Compare Acadia Healthcare Company Inc (ACHC) vs Enveric Biosciences Inc (ENVB) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Acadia Healthcare Company Inc vs Enveric Biosciences Inc — how do they compare? Acadia Healthcare Company Inc trades at $30.78 (market cap $2.94B), while Enveric Biosciences Inc trades at $1.37 (market cap $5.84M). The key difference: Acadia Healthcare Company Inc is far larger — about 503.4× Enveric Biosciences Inc's market cap, and Acadia Healthcare Company Inc is trading nearer its 52-week high, Enveric Biosciences Inc nearer its low. Which is the better fit depends on your goals.
| ACHC | ENVB | |
|---|---|---|
Market Cap | $2.94B | $5.84M |
Sector | Health | Health |
52-Week High | $31.92 | $17.40 |
52-Week Low | $11.68 | $1.28 |
Enterprise Value | $5.45B | $932.52K |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACHC trades at $31.09, down 2.57% today but maintains a bullish technical outlook with strong moving average support. The company shows operational strength with three consecutive earnings beats, though profitability remains challenged with a -32.84% net margin. Analyst consensus is strongly bullish with 68% buy ratings, while recent news highlights the company's strategic shift toward profitability and rising behavioral health demand.
The stock presents a mixed opportunity with strong technical momentum and analyst support offset by persistent profitability challenges. Key catalysts include continued earnings outperformance and successful execution of the turnaround strategy, while risks center on margin pressures and high short interest that could limit upside potential.
ENVB trades at $1.48, up 2.07% today, with a bearish technical signal from moving averages but neutral oscillators. The company reported a net loss of $8.77M for 2025, with negative ROE and ROA, yet consistently beat earnings expectations. Recent news highlights participation in investor conferences and progress with its neuroplastogen candidate EB-003, including IND-enabling studies.
The outlook is mixed: strong analyst support (75% buy ratings) and positive clinical updates contrast with deep losses and bearish technicals. Key risks include clinical trial outcomes and cash burn, while institutional financing provides near-term stability. Upside depends on successful drug development.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Acadia Healthcare Company Inc
Acadia Healthcare is a leading provider of behavioral healthcare services across the US and Puerto Rico. It operates a network of psychiatric hospitals, residential treatment centers, and clinics for mental health and addiction recovery.
Read more on ACHC →About Enveric Biosciences Inc
Enveric Biosciences is a biotechnology company focused on developing next-generation psychedelic-inspired therapies for mental health and neuropsychiatric disorders.
Read more on ENVB →
